Onxeo: Availability of 2021 Annual Financial Report

Paris – (Business Wire) – Regulatory News:

Onxeo SA (Euronext Glow Paris: ALONX, Nasdak First North Copenhagen: ONXEO), Onxeo ” Where ” society A clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA damage response (DDR) mechanisms to combat rare or resistant cancers today publishes its annual financial report 2021. Was announced.

The 2021 annual financial report is available on our website.

About Onxeo

Onxeo (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO) is a new anti-cancer by targeting tumor DNA function through an unparalleled mechanism of action in the highly sought after field of DNA damage response (DDR). A clinical biotechnology company that develops cancer drugs. We focus on developing innovative first-in-class or disruptive compounds (internal, acquisition, or licensing) from translational research to human proof-of-concept, a turning point that creates value. Attractive for potential partners.

Plato Is Onxeo’s decoy oligonucleotide chemistry platform, committed to the creation of new and innovative compounds aimed at expanding our product portfolio.

AsiDNA, Plato’s lead compounds are highly differentiated first-in-call clinical stage candidates in the field of DNA damage response (DDR) applied in oncology. Its decoy and agonist mechanisms, which act upstream of multiple DDR pathways, are capable of preventing or abolishing tumor resistance to targeted therapies such as PARP inhibitors, and are potent with damaging agent tumor DNA such as radiation / chemotherapy. It brings unique antitumor properties such as synergistic effects. AsiDNA is currently in clinical trials combining difficult-to-treat solid tumors.

OX401 Is a new candidate produced by platON, designed as a potent PARP agonist, which acts on both DNA damage response and immune response activation without inducing resistance. OX401 is in the optimization and preclinical proof-of-concept stage, alone or in combination with immunotherapy.

For more information, please visit www.onxeo.com.

Description of future prospects

This press release contains, implicitly or explicitly, statements about specific future prospects related to Onxeo and its business. These statements depend on certain known or unknown risks, uncertainties, and other factors. These factors can cause Onxeo’s actual results, financial condition, performance, or outcomes to differ materially from those expressed or implied by such. A description of the future outlook. Onxeo has issued this press release as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events, etc. Risk factors described in the latest document for an explanation of the risks and uncertainties that Onxeo’s actual results, financial position, performance or performance may differ from those contained in the forward-looking statements. Or see Others. Regular financial reports or press releases available free of charge on our website (www.onxeo.com) and / or AMF (www.amf-france.org).

contact address

Onxeo
Valerie Leroy

[email protected]
+33 1 45 58 76 00

Public relations

Nicholas Merigot
NewCap

[email protected]
+33 1 44 71 94 98

Investor Public Relations / Strategic Communication

Dušan Orešan ský / Emmanuel Yuin

NewCap

[email protected]
+33 1 44 71 94 92 92